Celldex Therapeutics, Inc.
NASDAQ:CLDXBiotechnology
+$0.16 today
- Market cap
- $2.16B
- Beta
- 0.93
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$4.26
Volume 0.68M
Average 0.94M
CLDX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Celldex Therapeutics, Inc.NASDAQ: CLDX
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses growth accelerates
Q3 FY2026 operating expenses of $82.25M rose 669.7% year over year, ahead of the +278.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +101.5% a year.
Context
- Operating expenses amounted to 19260.0% of revenue in FY2025, up 18710.9 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +669.7% holds above the trailing-twelve-month pace of +278.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 288.9M USD
- Year-over-year change
- +649.5%
- 4-year CAGR
- +89.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 288.9M | +649.5% |
| FY2024 | 2024-12-31 | 38.55M | -11.2% |
| FY2023 | 2023-12-31 | 43.41M | +22.9% |
| FY2022 | 2022-12-31 | 35.33M | +56.5% |
| FY2021 | 2021-12-31 | 22.58M | — |
Operating Expenses vs competitors
How CLDX compares with its peers on the latest reported figures
- CLDX's LTM Sep 2026 operating expenses of $333.75M is the 2nd highest of the 10 companies compared; the peer median is $173.51M.
- Its year-over-year change of +278.1% is the highest of 9, against a peer median of +7.0%.
- Operating expenses amounts to 297994.6% of revenue for CLDX, versus a peer median of 110.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $596M | -0.7% | +16.7% | 509.4% | |
| LTM Sep 2026 | $333.75M | +278.1% | +101.5% | 297994.6% | |
| LTM Aug 2026 | $317.52M | +142.5% | +109.8% | 45.2% | |
| LTM Sep 2026 | $299.94M | +54.6% | +80.8% | — | |
| LTM Jun 2026 | $261.54M | +14.7% | +83.3% | 249.1% | |
| LTM Mar 2026 | $173.51M | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $74.43M | +18.8% | +19.7% | — | |
| LTM Mar 2026 | $56.39M | -15.6% | -12.1% | 45.5% | |
| LTM Jun 2024 | $36.55M | — | -32.2% | 4480.0% | |
| LTM Mar 2026 | $33.28M | -2.6% | -8.4% | 45.8% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CLDX) | $173.51M | +7.0% | +16.7% | 110.5% | |
Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.65M | 2.36M | 6.88M | 7.02M | 1.5M |
| Cost of Revenue | 53.31M | 82.26M | 118.01M | 163.55M | 0 |
| Gross Profit | (48.66M) | (79.9M) | (111.13M) | (156.53M) | 1.5M |
| Gross Margin | -1046.2% | -3389.9% | -1614.5% | -2229.8% | 100.0% |
| Research & Development | 56.81M | 82.26M | 118.01M | 163.55M | 245.1M |
| Selling, General & Admin | 20.49M | 27.2M | 30.91M | 38.55M | 43.8M |
| Operating Expenses | 22.58M | 35.33M | 43.41M | 38.55M | 288.9M |
| Depreciation & Amortization | 3.07M | 2.9M | 3.01M | 3.18M | 3.38M |
| EBITDA | (66.08M) | (104.2M) | (139.03M) | (154.69M) | (255.42M) |
| EBITDA Margin | -1420.8% | -4420.9% | -2020.0% | -2203.5% | -17028.0% |
| Operating Income | (71.24M) | (115.23M) | (154.54M) | (195.08M) | (287.4M) |
| Operating Margin | -1531.8% | -4889.0% | -2245.3% | -2778.9% | -19160.0% |
| Interest Income | 505K | 2.91M | 13.11M | 37.22M | 28.61M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 505K | 2.91M | 13.11M | 37.22M | 28.6M |
| Income Before Tax | (70.74M) | (112.33M) | (141.43M) | (157.86M) | (258.8M) |
| Pre-Tax Margin | -1520.9% | -4765.6% | -2054.8% | -2248.8% | -17253.3% |
| Income Tax Expense | (227K) | 0 | 0 | 0 | 0 |
| Net Income | (70.51M) | (112.33M) | (141.43M) | (157.86M) | (258.8M) |
| Net Margin | -1516.0% | -4765.6% | -2054.8% | -2248.8% | -17253.3% |
| EPS (Basic) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| EPS (Diluted) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| Weighted Avg Shares | 42.87M | 46.89M | 48.45M | 64.4M | 66.5M |
| Weighted Avg Shares (Diluted) | 42.87M | 46.89M | 48.45M | 64.4M | 66.5M |
Celldex Therapeutics, Inc.
NASDAQ:CLDX
Intrinsic Alpha fair value
Locked
Current Price
$27.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.